Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016

Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis

Authors: Qiaohong Ouyang, Zhongxiang Duan, Jixiao Lei, Guangli Jiao

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

The early diagnosis of prostate cancer (PCa) appears to be of vital significance for the provision of appropriate treatment programs. Even though several sophisticated imaging techniques such as positron emission tomography/computed tomography (PET/CT) and elastosonography (ES) have already been developed for PCa diagnosis, the diagnostic accuracy of these imaging techniques is still controversial to some extent. Therefore, a comprehensive meta-analysis in this study was performed to compare the accuracy of various diagnostic imaging methods for PCa, including 11C-choline PET/CT, 11C-acetate PET/CT, 18F-fluorocholine PET/CT, 18F-fluoroglucose PET/CT, transrectal real-time elastosonography (TRTE), and shear-wave elastosonography (SWE). The eligible studies were identified through systematical searching for the literature in electronic databases including PubMed, Cochrane, and Web of Science. On the basis of the fixed-effects model, the pooled sensitivity (SEN), specificity (SPE), and area under the receiver operating characteristics curve (AUC) were calculated to estimate the diagnostic accuracy of 11C-choline PET/CT, 11C-acetate PET/CT, 18F-fluorocholine (FCH) PET/CT, 18F-fluoroglucose (FDG) PET/CT, TRTE, and SWE. All the statistical analyses were conducted with R language Software. The present meta-analysis incorporating a total of 82 studies demonstrated that the pooled sensitivity of the six imaging techniques were sorted as follows: SWE > 18F-FCH PET/CT > 11C-choline PET/CT > TRTE > 11C-acetate PET/CT > 18F-FDG PET/CT; the pooled specificity were also compared: SWE > 18F-FCH PET/CT > 11C-choline PET/CT > TRTE > 18F-FDG PET/CT > 11C-acetate PET/CT; finally, the pooled diagnostic accuracy of the six imaging techniques based on AUC were ranked as below: SWE > 18F-FCH PET/CT > 11C-choline PET/CT > TRTE > 11C-acetate PET/CT > 18F-FDG PET/CT. SWE and 18F-FCH PET/CT imaging could offer more assistance in the early diagnosis of PCa than any other studied imaging techniques. However, the diagnostic ranking of the six imaging techniques might not be applicable to the clinical phase due to the shortage of stratified analysis.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clinicians. 2015;65:5–29.CrossRef
2.
Halpern EJ, Frauscher F, Rosenberg M, Gomella LG. Directed biopsy during contrast-enhanced sonography of the prostate. AJR Am J Roentgenol. 2002;178:915–9.PubMedCrossRef
3.
Correas JM, Tissier AM, Khairoune A, Vassiliu V, Mejean A, Helenon O, et al. Prostate cancer: diagnostic performance of real-time shear-wave elastography. Radiology. 2015;275:280–9.PubMedCrossRef
4.
Hodgson R, Huang YT, Steinke K, Ravi Kumar AS. FDG-PET/CT in evaluation and prognostication of primary prostate lymphoma. Clin Nucl Med. 2010;35:418–20.PubMedCrossRef
5.
Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nuclear Med : Off Public, Soc Nuclear Med. 2006;47:1249–54.
6.
Beheshti M, Vali R, Langsteger W. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316–7. author reply 1318-1319.PubMedCrossRef
7.
Jambor I, Borra R, Kemppainen J, Lepomaki V, Parkkola R, Dean K, et al. Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy. J Nuclear Med : Off Public, Soc Nuclear Med. 2010;51:1676–83.CrossRef
8.
Heck MM, Souvatzoglou M, Retz M, Nawroth R, Kubler H, Maurer T, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:694–701.PubMedCrossRef
9.
Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)C-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013;189:1308–13.PubMedCrossRef
10.
Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26.PubMedCrossRef
11.
Xu G, Feng L, Yao M, Wu J, Guo L, Yao X, et al. A new 5-grading score in the diagnosis of prostate cancer with real-time elastography. Int J Clin Experiment Pathol. 2014;7:4128–35.
12.
Brock M, Eggert T, Palisaar RJ, Roghmann F, Braun K, Loppenberg B, et al. Multiparametric ultrasound of the prostate: adding contrast enhanced ultrasound to real-time elastography to detect histopathologically confirmed cancer. J Urol. 2013;189:93–8.PubMedCrossRef
13.
Jambor I, Borra R, Kemppainen J, Lepomaki V, Parkkola R, Dean K, et al. Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. Eur J Radiol. 2012;81:2966–72.PubMedCrossRef
14.
Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513–9.PubMedCrossRef
15.
Mohsen B, Giorgio T, Rasoul ZS, Werner L, Ali GR, Reza DK, et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 2013;112:1062–72.PubMedCrossRef
16.
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106–17.PubMedCrossRef
17.
Salomon G. Transrectal sonoelastography in the detection of prostate cancers: a meta-analysis. BJU Int. 2012;110:E621.PubMedCrossRef
18.
Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607–11.PubMedCrossRef
19.
Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:68–78.PubMedCrossRef
20.
Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int. 2007;99:1415–20.PubMedCrossRef
21.
Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric mr imaging with endorectal coil. J Nuclear Med : Off Public, Soc Nuclear Med. 2014;55:223–32.CrossRef
22.
Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, et al. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. J Urol. 2014;192:103–10.PubMedCrossRef
23.
Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, et al. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol. 2013;189:105–10.PubMedCrossRef
24.
Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (1)(1)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83:1486–92.PubMedCrossRef
25.
Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011;38:1985–9.PubMedCrossRef
26.
Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S, et al. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res. 2011;17:7673–83.PubMedCrossRef
27.
Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125–30.PubMedCrossRef
28.
Bertagna F, Abuhilal M, Bosio G, Simeone C, Rossini P, Pizzocaro C, et al. Role of (1)(1)C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation. Jpn J Radiol. 2011;29:394–404.PubMedCrossRef
29.
Winter A, Uphoff J, Henke RP, Wawroschek F. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int. 2010;84:418–23.PubMedCrossRef
30.
Watanabe H, Kanematsu M, Kondo H, Kako N, Yamamoto N, Yamada T, et al. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J Magnet Reson Imag : JMRI. 2010;31:1151–6.CrossRef
31.
Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106–16.PubMedCrossRef
32.
Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9.PubMedCrossRef
33.
Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:160–4.PubMedCrossRef
34.
Winter A, Uphoff J, Henke RP, Wawroschek F. [First results of PET/CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy]. Aktuelle Urol. 2009;40:294–9.PubMedCrossRef
35.
Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009;27:619–25.PubMedCrossRef
36.
Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392–401.PubMedCrossRef
37.
Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9–17.PubMedCrossRef
38.
Li X, Liu Q, Wang M, Jin X, Yao S, Liu S, et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med. 2008;33:671–6.PubMedCrossRef
39.
Igerc I, Kohlfurst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:976–83.PubMedCrossRef
40.
Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065–73.PubMedCrossRef
41.
Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007;244:797–806.PubMedCrossRef
42.
Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:45–53.PubMedCrossRef
43.
Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9.PubMedCrossRef
44.
Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–93.PubMedCrossRef
45.
Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954–60. discussion 960.PubMedCrossRef
46.
Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nuclear Med : Off Public, Soc Nuclear Med. 2005;46:1642–9.
47.
Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31:317–24.PubMedCrossRef
48.
Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–9.PubMedCrossRef
49.
Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int. 2012;110:1666–71.PubMedCrossRef
50.
Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81:700–8.PubMedCrossRef
51.
Oprea-Lager DE, Vincent AD, van Moorselaar RJ, Gerritsen WR, van den Eertwegh AJ, Eriksson J, et al. Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One. 2012;7:e48430.PubMedPubMedCentralCrossRef
52.
McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, et al. (1)(8)F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38:14–22.PubMedCrossRef
53.
Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imag. 2011;55:448–57.
54.
Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer. 2010;46:449–55.PubMedCrossRef
55.
Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int. 2010;106:639–43. discussion 644.PubMedCrossRef
56.
Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33.PubMedCrossRef
57.
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Molec Imag Biol : MIB :Off Public Acad Molec Imag. 2009;11:446–54.CrossRef
58.
Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. La Radiol Med. 2008;113:895–904.CrossRef
59.
Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–63.PubMedCrossRef
60.
Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;176:2014–8. discussion 2018-2019.PubMedCrossRef
61.
Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252–5.PubMedCrossRef
62.
Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nuclear Med : Off Public, Soc Nuclear Med. 2013;54:699–706.CrossRef
63.
Mena E, Turkbey B, Mani H, Adler S, Valera VA, Bernardo M, et al. 11C-acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nuclear Med : Off Public, Soc Nuclear Med. 2012;53:538–45.CrossRef
64.
Yang Z, Hu S, Cheng J, Xu J, Shi W, Zhu B, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clin Imaging. 2014;38:470–4.PubMedCrossRef
65.
Hwang I, Chong A, Jung SI, Hwang EC, Kim SO, Kang TW, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27:140–5.PubMedCrossRef
66.
Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol. 2013;31:262–9.PubMedCrossRef
67.
Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, Sato H, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;26:138–45.PubMedCrossRef
68.
Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25:21–7.PubMedCrossRef
69.
Zhang Y, Tang J, Liang HD, Lv FQ, Song ZG. Transrectal real-time tissue elastography—an effective way to distinguish benign and malignant prostate tumors. Asian Pacific J Cancer Prevent : APJCP. 2014;15:1831–5.CrossRef
70.
Nygard Y, Haukaas SA, Halvorsen OJ, Gravdal K, Frugard J, Akslen LA, et al. A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting. BJU Int. 2014;113:E90–97.PubMedCrossRef
71.
Taverna G, Magnoni P, Giusti G, Seveso M, Benetti A, Hurle R, Colombo P, Minuti F, Grizzi F, Graziotti P. Impact of real-time elastography versus systematic prostate biopsy method on cancer detection rate in men with a serum prostate-specific antigen between 2.5 and 10 ng/ml. ISRN oncology 2013;2013:584672.
72.
Zhang Y, Tang J, Li YM, Fei X, Lv FQ, He EH, et al. Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography. Eur J Radiol. 2012;81:857–62.PubMedCrossRef
73.
Rausch S, Alt W, Arps H, Alt B, Kalble T. The utility of transrectal sonoelastography in preoperative prostate cancer assessment. Med Ultrasonograp. 2012;14:182–6.CrossRef
74.
Yan Z, Jie T, Yan-Mi L, Xiang F, Liu-Quan C, En-Hui H, et al. Role of transrectal real-time tissue elastography in the diagnosis of prostate cancer. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae. 2011;33:175–9.PubMed
75.
Kapoor A, Mahajan G, Sidhu BS. Real-time elastography in the detection of prostate cancer in patients with raised PSA level. Ultrasound Med Biol. 2011;37:1374–81.PubMedCrossRef
76.
Giurgiu CR, Manea C, Crisan N, Bungardean C, Coman I, Dudea SM. Real-time sonoelastography in the diagnosis of prostate cancer. Med Ultrasonograp. 2011;13:5–9.
77.
Tsutsumi M, Miyagawa T, Matsumura T, Endo T, Kandori S, Shimokama T, et al. Real-time balloon inflation elastography for prostate cancer detection and initial evaluation of clinicopathologic analysis. AJR Am J Roentgenol. 2010;194:W471–476.PubMedCrossRef
78.
Romagnoli A, Autieri G, Centrella D, Gastaldi C, Pedaci G, Rivolta L, et al. [Real-time elastography in the diagnosis of prostate cancer: personal experience]. Urologia. 2010;77:248–53.PubMed
79.
Aigner F, Pallwein L, Junker D, Schafer G, Mikuz G, Pedross F, et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol. 2010;184:913–7.PubMedCrossRef
80.
Ferrari FS, Scorzelli A, Megliola A, Drudi FM, Trovarelli S, Ponchietti R. Real-time elastography in the diagnosis of prostate tumor. J Ultrasound. 2009;12:22–31.PubMedPubMedCentralCrossRef
81.
Pallwein L, Mitterberger M, Pinggera G, Aigner F, Pedross F, Gradl J, et al. Sonoelastography of the prostate: comparison with systematic biopsy findings in 492 patients. Eur J Radiol. 2008;65:304–10.PubMedCrossRef
82.
Kamoi K, Okihara K, Ochiai A, Ukimura O, Mizutani Y, Kawauchi A, et al. The utility of transrectal real-time elastography in the diagnosis of prostate cancer. Ultrasound Med Biol. 2008;34:1025–32.PubMedCrossRef
83.
Eggert T, Khaled W, Wenske S, Ermert H, Noldus J. [Impact of elastography in clinical diagnosis of prostate cancer. a comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies]. Der Urologe Ausg A. 2008;47:1212–7.PubMedCrossRef
84.
Tsutsumi M, Miyagawa T, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, et al. The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis. Int J Clin Oncol. 2007;12:250–5.PubMedCrossRef
85.
Sumura M, Shigeno K, Hyuga T, Yoneda T, Shiina H, Igawa M. Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study. Int J Urol : Off J Jap Urol Assoc. 2007;14:811–6.CrossRef
86.
Pallwein L, Mitterberger M, Struve P, Pinggera G, Horninger W, Bartsch G, et al. Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int. 2007;100:42–6.PubMedCrossRef
87.
Pallwein L, Mitterberger M, Struve P, Horninger W, Aigner F, Bartsch G, et al. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol. 2007;17:2278–85.PubMedCrossRef
88.
Cochlin DL, Ganatra RH, Griffiths DF. Elastography in the detection of prostatic cancer. Clin Radiol. 2002;57:1014–20.PubMedCrossRef
89.
Ahmad S, Cao R, Varghese T, Bidaut L, Nabi G. Transrectal quantitative shear wave elastography in the detection and characterisation of prostate cancer. Surg Endosc. 2013;27:3280–7.PubMedCrossRef
90.
Barr RG, Memo R, Schaub CR. Shear wave ultrasound elastography of the prostate: initial results. Ultrasound Quart. 2012;28:13–20.CrossRef
91.
92.
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90.PubMed
93.
Seitz M, Scher B, Scherr M, Tilki D, Schlenker B, Gratzke C, et al. [Imaging procedures to diagnose prostate cancer]. Der Urologe Ausg A. 2007;46:W1435–1446. quiz W1447-1438.PubMedCrossRef
94.
Beyersdorff D, Taymoorian K, Knosel T, Schnorr D, Felix R, Hamm B, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol. 2005;185:1214–20.PubMedCrossRef
95.
Miyagawa T, Tsutsumi M, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, et al. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. Jpn J Clin Oncol. 2009;39:394–8.PubMedCrossRef
96.
Konig K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences with real-time elastography guided biopsies of the prostate. J Urol. 2005;174:115–7.PubMedCrossRef
97.
Miyanaga N, Akaza H, Yamakawa M, Oikawa T, Sekido N, Hinotsu S, et al. Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. Int J Urol : Off J Jap Urol Assoc. 2006;13:1514–8.CrossRef
98.
Townsend DW. Dual-modality imaging: combining anatomy and function. J Nuclear Med : Off Public, Soc Nuclear Med. 2008;49:938–55.CrossRef
99.
Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med. 2011;36:192–8.PubMedPubMedCentralCrossRef
100.
Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A. The clinical advances of fluorine-2-D-deoxyglucose—positron emission tomography/computed tomography in urological cancers. Int J Urol : Off J Jap Urol Assoc. 2010;17:501–11.CrossRef
101.
Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492–5.PubMedCrossRef
102.
Richter JA, Rodriguez M, Rioja J, Penuelas I, Marti-Climent J, Garrastachu P, et al. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Molec Imag Biol : MIB : Off Public Acad Molec Imag. 2010;12:210–7.CrossRef
103.
Fanti S, Nanni C, Lopci E, Castellucci P, Rubello D, Farsad M, et al. Imaging with (11)carbon labelled PET tracers. Nucl Med Commun. 2010;31:613–6.PubMedCrossRef
104.
Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:e26–32.PubMedCrossRef
105.
Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin Nuclear Med. 2009;48:1–9. quiz N2-3.
106.
Ginat DT, Destounis SV, Barr RG, Castaneda B, Strang JG, Rubens DJ. US elastography of breast and prostate lesions. Radiograp : Rev Public Radiol Soc North Am Inc. 2009;29:2007–16.CrossRef
Metadata
Title
Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis
Authors
Qiaohong Ouyang
Zhongxiang Duan
Jixiao Lei
Guangli Jiao
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4113-8

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression

Original Article

Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer

Original Article

HBx interacted with Smad4 to deprive activin a growth inhibition function in hepatocyte HL7702 on CRM1 manner

Original Article

The roles of mitochondria in radiation-induced autophagic cell death in cervical cancer cells

Original Article

The plasma lncRNA acting as fingerprint in non-small-cell lung cancer

Original Article

CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits